1
|
Weng J, Zheng G, Wen J, Yang J, Yang Q, Zheng X, Yan Q. Construction and application of microneedle-mediated photothermal therapy and immunotherapy combined anti-tumor drug delivery system. Drug Deliv 2023; 30:2232950. [PMID: 37439010 DOI: 10.1080/10717544.2023.2232950] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/14/2023] Open
Abstract
Conventional treatments for tumors were frequently accompanied by drawbacks and side effects. It might be useful to use the revolutionary microneedle technology which combines photothermal therapy with tumor immunotherapy. In this study, we created a microneedle drug delivery system with mercapto-modified gold nanorods and immune checkpoint blocker anti-PD-1 polypeptide. With good mechanical strength, the microneedle system can efficiently penetrate the skin and deliver drugs. When inserted into human skin, anti-PD-1 peptides and gold nanorods can be released, boosting the capacity of cytotoxic T lymphocytes to destroy tumor cells. Additionally, the elimination of the tumor is aided by the production of heat while being exposed to near-infrared light. This microneedle drug delivery system can enhance the immunological reaction and prolong the survival time of mice. Moreover, it has been demonstrated that the system has mild toxic and side effects on normal tissues and can effectively inhibit the growth of tumors, indicating a bright prospect for the treatment of cancers.
Collapse
Affiliation(s)
- Jiaqi Weng
- College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, P.R. China
- Institute of Laser Advanced Manufacturing, Zhejiang University of Technology, Hangzhou, Zhejiang, P.R. China
- College of Mechanical Engineering, Zhejiang University of Technology, Hangzhou, Zhejiang, P.R. China
| | - Gensuo Zheng
- College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, P.R. China
| | - Jiaoli Wen
- College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, P.R. China
| | - Jing Yang
- College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, P.R. China
| | - Qingliang Yang
- College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, P.R. China
| | - Xi Zheng
- Analysis Center of Agrobiology and Environmental Sciences, Zhejiang University, Hangzhou, P.R. China
| | - Qinying Yan
- College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, P.R. China
| |
Collapse
|
2
|
Bartneck J, Hartmann AK, Stein L, Arnold-Schild D, Klein M, Stassen M, Marini F, Pielenhofer J, Meiser SL, Langguth P, Mack M, Muth S, Probst HC, Schild H, Radsak MP. Tumor-infiltrating CCR2 + inflammatory monocytes counteract specific immunotherapy. Front Immunol 2023; 14:1267866. [PMID: 37849753 PMCID: PMC10577317 DOI: 10.3389/fimmu.2023.1267866] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2023] [Accepted: 09/13/2023] [Indexed: 10/19/2023] Open
Abstract
Tumor development and progression is shaped by the tumor microenvironment (TME), a heterogeneous assembly of infiltrating and resident host cells, their secreted mediators and intercellular matrix. In this context, tumors are infiltrated by various immune cells with either pro-tumoral or anti-tumoral functions. Recently, we published our non-invasive immunization platform DIVA suitable as a therapeutic vaccination method, further optimized by repeated application (DIVA2). In our present work, we revealed the therapeutic effect of DIVA2 in an MC38 tumor model and specifically focused on the mechanisms induced in the TME after immunization. DIVA2 resulted in transient tumor control followed by an immune evasion phase within three weeks after the initial tumor inoculation. High-dimensional flow cytometry analysis and single-cell mRNA-sequencing of tumor-infiltrating leukocytes revealed cytotoxic CD8+ T cells as key players in the immune control phase. In the immune evasion phase, inflammatory CCR2+ PDL-1+ monocytes with immunosuppressive properties were recruited into the tumor leading to suppression of DIVA2-induced tumor-reactive T cells. Depletion of CCR2+ cells with specific antibodies resulted in prolonged survival revealing CCR2+ monocytes as important for tumor immune escape in the TME. In summary, the present work provides a platform for generating a strong antigen-specific primary and memory T cell immune response using the optimized transcutaneous immunization method DIVA2. This enables protection against tumors by therapeutic immune control of solid tumors and highlights the immunosuppressive influence of tumor infiltrating CCR2+ monocytes that need to be inactivated in addition for successful cancer immunotherapy.
Collapse
Affiliation(s)
- Joschka Bartneck
- III Department of Medicine - Hematology, Oncology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
| | - Ann-Kathrin Hartmann
- III Department of Medicine - Hematology, Oncology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
| | - Lara Stein
- Institute of Immunology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
| | - Danielle Arnold-Schild
- Institute of Immunology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
| | - Matthias Klein
- Institute of Immunology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
| | - Michael Stassen
- Institute of Immunology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
| | - Federico Marini
- Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
| | - Jonas Pielenhofer
- Institute of Pharmaceutical and Biomedical Sciences of the Johannes Gutenberg-University, Biopharmaceutics and Pharmaceutical Technology, Mainz, Germany
| | - Sophie Luise Meiser
- Institute of Pharmaceutical and Biomedical Sciences of the Johannes Gutenberg-University, Biopharmaceutics and Pharmaceutical Technology, Mainz, Germany
| | - Peter Langguth
- Institute of Pharmaceutical and Biomedical Sciences of the Johannes Gutenberg-University, Biopharmaceutics and Pharmaceutical Technology, Mainz, Germany
| | - Matthias Mack
- University Hospital Regensburg, Department Nephrology, Regensburg, Germany
| | - Sabine Muth
- Institute of Immunology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
| | - Hans-Christian Probst
- Institute of Immunology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
| | - Hansjörg Schild
- Institute of Immunology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
| | - Markus Philipp Radsak
- III Department of Medicine - Hematology, Oncology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
| |
Collapse
|
3
|
Wang H, Xu J, Xiang L. Microneedle-Mediated Transcutaneous Immunization: Potential in Nucleic Acid Vaccination. Adv Healthc Mater 2023; 12:e2300339. [PMID: 37115817 DOI: 10.1002/adhm.202300339] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2023] [Revised: 04/07/2023] [Indexed: 04/29/2023]
Abstract
Efforts aimed at exploring economical and efficient vaccination have taken center stage to combat frequent epidemics worldwide. Various vaccines have been developed for infectious diseases, among which nucleic acid vaccines have attracted much attention from researchers due to their design flexibility and wide application. However, the lack of an efficient delivery system considerably limits the clinical translation of nucleic acid vaccines. As mass vaccinations via syringes are limited by low patient compliance and high costs, microneedles (MNs), which can achieve painless, cost-effective, and efficient drug delivery, can provide an ideal vaccination strategy. The MNs can break through the stratum corneum barrier in the skin and deliver vaccines to the immune cell-rich epidermis and dermis. In addition, the feasibility of MN-mediated vaccination is demonstrated in both preclinical and clinical studies and has tremendous potential for the delivery of nucleic acid vaccines. In this work, the current status of research on MN vaccines is reviewed. Moreover, the improvements of MN-mediated nucleic acid vaccination are summarized and the challenges of its clinical translation in the future are discussed.
Collapse
Affiliation(s)
- Haochen Wang
- State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, 610041, China
| | - Junhua Xu
- Biopharmaceutical Research Institute, West China Hospital, Sichuan University, Chengdu, 610041, China
| | - Lin Xiang
- State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, 610041, China
- Department of Oral Implantology, West China Hospital of Stomatology, Sichuan University, Chengdu, 610041, China
| |
Collapse
|
4
|
Sonzogni A, Cabrera G, Lupi G, Gugliotta L, Gonzalez V, Marcipar I, Minari R. Film Forming Nanogels for Needle-free Transdermal Vaccination. Macromol Biosci 2022; 22:e2100515. [PMID: 35388617 DOI: 10.1002/mabi.202100515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2021] [Revised: 03/21/2022] [Indexed: 11/06/2022]
Abstract
Transcutaneous immunization (TCI) provides a valuable alternative approach to conventional vaccination because of the high accessibility and the exceptional immunological characteristics of the skin, but its application is limited by the low permeability of the stratum corneum. Although nanogels (NGs) have proven to enhance skin penetration of macromolecules with minimum damage, their use in TCI remains almost unexplored. In this context, this article evaluates the performance of novel film forming NGs (FF-NGs) as TCI. This TCI platform consists of NGs with multilobular morphology that positively combines the properties of crosslinked poly(N-vinylcaprolactam), like thermoresponsiveness and the ability to load and release a cargo, with the film forming capacity of low Tg lobes. FF-NGs and formed films were characterized at different levels. Formed films show to be able to uniformly load an antigenic protein and release it with a profile depending on the temperature and on their FF-NGs content. In-vivo studies have demonstrated that FF-NGs promote the penetration of not only an antigenic protein but also an adjuvant until the immunocompetent area of skin, generating an adjuvant-dependent specific immune response. Finally, this study provides a successful proof of concept that FF-NGs could be a powerful tool for transcutaneous release of complex formulations. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Ana Sonzogni
- Group of Polymers and Polymerization Reactors, INTEC (Universidad Nacional del Litoral-CONICET), Santa Fe, Argentina
| | - Gabriel Cabrera
- Facultad de Bioquímica y Ciencias Biológicas, Universidad Nacional del Litoral, Santa Fe, Argentina
| | - Giuliana Lupi
- Facultad de Bioquímica y Ciencias Biológicas, Universidad Nacional del Litoral, Santa Fe, Argentina
| | - Luis Gugliotta
- Group of Polymers and Polymerization Reactors, INTEC (Universidad Nacional del Litoral-CONICET), Santa Fe, Argentina.,Facultad de Ingeniería Química (Universidad Nacional del Litoral), Santa Fe, Argentina
| | - Verónica Gonzalez
- Group of Polymers and Polymerization Reactors, INTEC (Universidad Nacional del Litoral-CONICET), Santa Fe, Argentina.,Facultad de Bioquímica y Ciencias Biológicas, Universidad Nacional del Litoral, Santa Fe, Argentina
| | - Iván Marcipar
- Facultad de Bioquímica y Ciencias Biológicas, Universidad Nacional del Litoral, Santa Fe, Argentina
| | - Roque Minari
- Group of Polymers and Polymerization Reactors, INTEC (Universidad Nacional del Litoral-CONICET), Santa Fe, Argentina.,Facultad de Ingeniería Química (Universidad Nacional del Litoral), Santa Fe, Argentina
| |
Collapse
|
5
|
Hirobe S, Kawakita T, Yamasaki T, Ito S, Tachibana M, Okada N. Adjuvant Activity of CpG-Oligonucleotide Administered Transcutaneously in Combination with Vaccination Using a Self-Dissolving Microneedle Patch in Mice. Vaccines (Basel) 2021; 9:1480. [PMID: 34960226 DOI: 10.3390/vaccines9121480] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2021] [Revised: 12/09/2021] [Accepted: 12/10/2021] [Indexed: 11/17/2022] Open
Abstract
In this study, we investigated the mechanism of transcutaneous adjuvant activity of the CpG-oligonucleotide (K3) in mice. Transcutaneous immunization (TCI) with an ovalbumin-loaded self-dissolving microneedle patch (OVA-sdMN) and K3-loaded hydrophilic gel patch (HG) increased OVA-specific Th2- and Th1-type IgG subclass antibody titers more rapidly and strongly than those after only OVA-sdMN administration. However, the antigen-specific proliferation of OVA-specific CD4+ T cells was similar between the OVA-only and the OVA+K3 groups. Population analysis of various immune cells in draining lymph nodes (dLNs) in the primary immune response revealed that the OVA+K3 combination doubled the number of dLN cells, with the most significant increase in B cells. Phenotypic analysis by flow cytometry revealed that B-cell activation and maturation were promoted in the OVA+K3 group, suggesting that direct B-cell activation by K3 largely contributed to the rapid increase in antigen-specific antibody titer in TCI. In the secondary immune response, a significant increase in effector T cells and effector memory T cells, and an increase in memory B cells were observed in the OVA+K3 group compared with that in the OVA-only group. Thus, K3, as a transcutaneous adjuvant, can promote the memory differentiation of T and B cells.
Collapse
|
6
|
Weimer P, Rossi RC, Koester LS. Dissolving Microneedles Developed in Association with Nanosystems: A Scoping Review on the Quality Parameters of These Emerging Systems for Drug or Protein Transdermal Delivery. Pharmaceutics 2021; 13:pharmaceutics13101601. [PMID: 34683895 PMCID: PMC8538119 DOI: 10.3390/pharmaceutics13101601] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2021] [Revised: 09/24/2021] [Accepted: 09/27/2021] [Indexed: 12/20/2022] Open
Abstract
The largest organ of the body provides the main challenge for the transdermal delivery of lipophilic or high molecular weight drugs. To cross the main barrier of the skin, the stratum corneum, many techniques have been developed and improved. In the last 20 years, the association of microneedles with nanostructured systems has gained prominence for its versatility and for enabling targeted drug delivery. Currently, the combination of these mechanisms is pointed to as an emerging technology; however, some gaps need to be answered to transcend the development of these devices from the laboratory scale to the pharmaceutical market. It is known that the lack of regulatory guidelines for quality control is a hindrance to market conquest. In this context, this study undertakes a scoping review of original papers concerning methods applied to evaluate both the quality and drug/protein delivery of dissolving and hydrogel-forming microneedles developed in association with nanostructured systems.
Collapse
Affiliation(s)
- Patrícia Weimer
- Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre 90610-000, Brazil;
| | - Rochele Cassanta Rossi
- Programa de Pós-Graduação em Nutrição e Alimentos, Universidade do Vale do Rio dos Sinos (UNISINOS), São Leopoldo 93022-000, Brazil;
| | - Letícia Scherer Koester
- Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre 90610-000, Brazil;
- Correspondence: ; Tel.: +55-51-33085278; Fax: +55-51-33085437
| |
Collapse
|
7
|
Hong H, Wang X, Song X, Fawal GE, Wang K, Jiang D, Pei Y, Wang Z, Wang H. Transdermal delivery of interleukin-12 gene targeting dendritic cells enhances the anti-tumour effect of programmed cell death protein 1 monoclonal antibody. Biomater Transl 2021; 2:151-164. [PMID: 35836967 PMCID: PMC9255785 DOI: 10.12336/biomatertransl.2021.02.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/17/2021] [Revised: 06/04/2021] [Accepted: 06/07/2021] [Indexed: 01/17/2023]
Abstract
Recent studies have suggested that the anti-tumour effect of the programmed cell death protein 1 monoclonal antibody (aPD-1) depends on the expression of interleukin-12 (IL-12) by dendritic cells (DCs). Since DCs are abundant in skin tissues, transdermal delivery of IL-12 targeting DCs may significantly improve the anti-tumour effect of aPD-1. In this study, a novel mannosylated chitosan (MC)-modified ethosome (Eth-MC) was obtained through electrostatic adsorption. The Eth-MC loaded with plasmid containing the IL-12 gene (pIL-12@Eth-MC) stimulated DCs to express mature-related molecular markers such as CD86, CD80, and major histocompatibility complex-II in a targeted manner. The pIL-12@Eth-MC was then mixed with polyvinyl pyrrolidone solution to make microspheres using the electrospray technique, and sprayed onto the surface of electrospun silk fibroin-polyvinyl alcohol nanofibres to obtain a PVP-pIL-12@Eth-MC/silk fibroin-polyvinyl alcohol composite nanofibrous patch (termed a transcutaneous immunization (TCI) patch). The TCI patch showed a good performance on transdermal drug release. Animal experiments on melanoma-bearing mice showed that topical application of the TCI patches promoted the expression of IL-12 and inhibited the growth of tumour. Furthermore, combined application of the TCI patch and aPD-1 showed a stronger anti-tumour effect than aPD-1 monotherapy. The combination therapy significantly promoted the expression of IL-12, interferon-γ and tumour necrosis factor-α, the infiltration of CD4+ and CD8+ T cells into tumour tissues, and thus promoted the apoptosis of tumour cells. The present study provides a convenient and non-invasive strategy for improving the efficacy of immune checkpoint inhibitor therapy. This study was approved by the Institutional Animal Care and Use Committee at Donghua University (approval No. DHUEC-NSFC-2020-11) on March 31, 2020.
Collapse
Affiliation(s)
- Huoyan Hong
- Shanghai Engineering Research Centre of Nano-Biomaterials and Regenerative Medicine, Key Laboratory of Science & Technology of Eco-Textile (Ministry of Education), College of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai, China
| | - Xiaoyun Wang
- Department of Obstetrics & Gynaecology, Shanghai First People’s Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China
| | - Xinran Song
- Shanghai Engineering Research Centre of Nano-Biomaterials and Regenerative Medicine, Key Laboratory of Science & Technology of Eco-Textile (Ministry of Education), College of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai, China
| | - Gomaa El Fawal
- Shanghai Engineering Research Centre of Nano-Biomaterials and Regenerative Medicine, Key Laboratory of Science & Technology of Eco-Textile (Ministry of Education), College of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai, China,Department of Polymer Materials Research, Advanced Technology and New Materials Research Institute, Scientific Research and Technological Applications City (SRTA-City), New Borg El-Arab City, Alexandria, Egypt
| | - Kaili Wang
- Shanghai Engineering Research Centre of Nano-Biomaterials and Regenerative Medicine, Key Laboratory of Science & Technology of Eco-Textile (Ministry of Education), College of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai, China
| | - Di Jiang
- Shanghai Engineering Research Centre of Nano-Biomaterials and Regenerative Medicine, Key Laboratory of Science & Technology of Eco-Textile (Ministry of Education), College of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai, China
| | - Yifei Pei
- Shanghai Engineering Research Centre of Nano-Biomaterials and Regenerative Medicine, Key Laboratory of Science & Technology of Eco-Textile (Ministry of Education), College of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai, China
| | - Zhe Wang
- Shanghai Engineering Research Centre of Nano-Biomaterials and Regenerative Medicine, Key Laboratory of Science & Technology of Eco-Textile (Ministry of Education), College of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai, China
| | - Hongsheng Wang
- Shanghai Engineering Research Centre of Nano-Biomaterials and Regenerative Medicine, Key Laboratory of Science & Technology of Eco-Textile (Ministry of Education), College of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai, China,Corresponding author: Hongsheng Wang,
| |
Collapse
|
8
|
Andreata-Santos R, Alves RPDS, Pereira SA, Pereira LR, de Freitas CL, Pereira SS, Venceslau-Carvalho AA, Castro-Amarante MF, Favaro MTP, Mathias-Santos C, Amorim JH, Ferreira LCDS. Transcutaneous Administration of Dengue Vaccines. Viruses 2020; 12:v12050514. [PMID: 32384822 PMCID: PMC7290698 DOI: 10.3390/v12050514] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2020] [Revised: 03/26/2020] [Accepted: 04/03/2020] [Indexed: 12/28/2022] Open
Abstract
In the present study, we evaluated the immunological responses induced by dengue vaccines under experimental conditions after delivery via a transcutaneous (TC) route. Vaccines against type 2 Dengue virus particles (DENV2 New Guinea C (NGC) strain) combined with enterotoxigenic Escherichia coli (ETEC) heat-labile toxin (LT) were administered to BALB/c mice in a three-dose immunization regimen via the TC route. As a control for the parenteral administration route, other mouse groups were immunized with the same vaccine formulation via the intradermic (ID) route. Our results showed that mice vaccinated either via the TC or ID routes developed similar protective immunity, as measured after lethal challenges with the DENV2 NGC strain. Notably, the vaccine delivered through the TC route induced lower serum antibody (IgG) responses with regard to ID-immunized mice, particularly after the third dose. The protective immunity elicited in TC-immunized mice was attributed to different antigen-specific antibody properties, such as epitope specificity and IgG subclass responses, and cellular immune responses, as determined by cytokine secretion profiles. Altogether, the results of the present study demonstrate the immunogenicity and protective properties of a dengue vaccine delivered through the TC route and offer perspectives for future clinical applications.
Collapse
Affiliation(s)
- Robert Andreata-Santos
- Vaccine Development Laboratory, Microbiology Department, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-000, Brazil; (R.A.-S.); (R.P.d.S.A.); (S.A.P.); (L.R.P.); (C.L.d.F.); (S.S.P.); (A.A.V.-C.); (M.F.C.-A.); (M.T.P.F.); (C.M.-S.)
| | - Rúbens Prince dos Santos Alves
- Vaccine Development Laboratory, Microbiology Department, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-000, Brazil; (R.A.-S.); (R.P.d.S.A.); (S.A.P.); (L.R.P.); (C.L.d.F.); (S.S.P.); (A.A.V.-C.); (M.F.C.-A.); (M.T.P.F.); (C.M.-S.)
| | - Sara Araujo Pereira
- Vaccine Development Laboratory, Microbiology Department, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-000, Brazil; (R.A.-S.); (R.P.d.S.A.); (S.A.P.); (L.R.P.); (C.L.d.F.); (S.S.P.); (A.A.V.-C.); (M.F.C.-A.); (M.T.P.F.); (C.M.-S.)
| | - Lennon Ramos Pereira
- Vaccine Development Laboratory, Microbiology Department, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-000, Brazil; (R.A.-S.); (R.P.d.S.A.); (S.A.P.); (L.R.P.); (C.L.d.F.); (S.S.P.); (A.A.V.-C.); (M.F.C.-A.); (M.T.P.F.); (C.M.-S.)
| | - Carla Longo de Freitas
- Vaccine Development Laboratory, Microbiology Department, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-000, Brazil; (R.A.-S.); (R.P.d.S.A.); (S.A.P.); (L.R.P.); (C.L.d.F.); (S.S.P.); (A.A.V.-C.); (M.F.C.-A.); (M.T.P.F.); (C.M.-S.)
| | - Samuel Santos Pereira
- Vaccine Development Laboratory, Microbiology Department, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-000, Brazil; (R.A.-S.); (R.P.d.S.A.); (S.A.P.); (L.R.P.); (C.L.d.F.); (S.S.P.); (A.A.V.-C.); (M.F.C.-A.); (M.T.P.F.); (C.M.-S.)
| | - Alexia Adrianne Venceslau-Carvalho
- Vaccine Development Laboratory, Microbiology Department, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-000, Brazil; (R.A.-S.); (R.P.d.S.A.); (S.A.P.); (L.R.P.); (C.L.d.F.); (S.S.P.); (A.A.V.-C.); (M.F.C.-A.); (M.T.P.F.); (C.M.-S.)
| | - Maria Fernanda Castro-Amarante
- Vaccine Development Laboratory, Microbiology Department, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-000, Brazil; (R.A.-S.); (R.P.d.S.A.); (S.A.P.); (L.R.P.); (C.L.d.F.); (S.S.P.); (A.A.V.-C.); (M.F.C.-A.); (M.T.P.F.); (C.M.-S.)
| | - Marianna Teixeira Pinho Favaro
- Vaccine Development Laboratory, Microbiology Department, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-000, Brazil; (R.A.-S.); (R.P.d.S.A.); (S.A.P.); (L.R.P.); (C.L.d.F.); (S.S.P.); (A.A.V.-C.); (M.F.C.-A.); (M.T.P.F.); (C.M.-S.)
| | - Camila Mathias-Santos
- Vaccine Development Laboratory, Microbiology Department, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-000, Brazil; (R.A.-S.); (R.P.d.S.A.); (S.A.P.); (L.R.P.); (C.L.d.F.); (S.S.P.); (A.A.V.-C.); (M.F.C.-A.); (M.T.P.F.); (C.M.-S.)
| | - Jaime Henrique Amorim
- Center for Biological and Health Sciences, Federal University of Western Bahia, Bahia 47810-047, Brazil;
| | - Luís Carlos de Souza Ferreira
- Vaccine Development Laboratory, Microbiology Department, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-000, Brazil; (R.A.-S.); (R.P.d.S.A.); (S.A.P.); (L.R.P.); (C.L.d.F.); (S.S.P.); (A.A.V.-C.); (M.F.C.-A.); (M.T.P.F.); (C.M.-S.)
- Correspondence: ; Tel.: +55-11-3091-7356
| |
Collapse
|
9
|
Ito S, Hirobe S, Kawakita T, Saito M, Quan YS, Kamiyama F, Ishii KJ, Nagao M, Fujisawa T, Tachibana M, Okada N. Characteristic of K3 (CpG-ODN) as a Transcutaneous Vaccine Formulation Adjuvant. Pharmaceutics 2020; 12:E267. [PMID: 32183437 DOI: 10.3390/pharmaceutics12030267] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2020] [Revised: 03/06/2020] [Accepted: 03/13/2020] [Indexed: 01/18/2023] Open
Abstract
Transcutaneous immunization (TCI) is easy to use, minimally invasive, and has excellent efficacy in vaccines against infections. We focused on toll-like receptor (TLR) ligands as applicable adjuvants for transcutaneous formulations and characterized immune responses. TCI was performed using poke-and-patch methods, in which puncture holes are formed with a polyglycolic acid microneedle on the back skin of mice. Various TLR ligands were applied to the puncture holes and covered with an ovalbumin-loaded hydrophilic gel patch. During the screening process, K3 (CpG-oligonucleotide) successfully produced more antigen-specific antibodies than other TLR ligands and induced T helper (Th) 1-type polarization. Transcutaneously administered K3 was detected in draining lymph nodes and was found to promote B cell activation and differentiation, suggesting a direct transcutaneous adjuvant activity on B cells. Furthermore, a human safety test of K3-loaded self-dissolving microneedles (sdMN) was performed. Although a local skin reaction was observed at the sdMN application site, there was no systemic side reaction. In summary, we report a K3-induced Th1-type immune response that is a promising adjuvant for transcutaneous vaccine formulations using MN and show that K3-loaded sdMN can be safely applied to human skin.
Collapse
|
10
|
Pielenhofer J, Sohl J, Windbergs M, Langguth P, Radsak MP. Current Progress in Particle-Based Systems for Transdermal Vaccine Delivery. Front Immunol 2020; 11:266. [PMID: 32174915 PMCID: PMC7055421 DOI: 10.3389/fimmu.2020.00266] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2019] [Accepted: 02/03/2020] [Indexed: 12/31/2022] Open
Abstract
Transcutaneous immunization (TCI) via needle-free and non-invasive drug delivery systems is a promising approach for overcoming the current limitations of conventional parenteral vaccination methods. The targeted access to professional antigen-presenting cell (APC) populations within the skin, such as Langerhans cells (LCs), various dermal dendritic cells (dDCs), macrophages, and others makes the skin an ideal vaccination site to specifically shape immune responses as required. The stratum corneum (SC) of the skin is the main penetration barrier that needs to be overcome by the vaccine components in a coordinated way to achieve optimal access to dermal APC populations that induce priming of T-cell or B-cell responses for protective immunity. While there are numerous approaches to penetrating the SC, such as electroporation, sono- or iontophoresis, barrier and ablative methods, jet and powder injectors, and microneedle-mediated transport, we will focus this review on the recent progress made in particle-based systems for TCI. This particular approach delivers vaccine antigens together with adjuvants to perifollicular APCs by diffusion and deposition in hair follicles. Different delivery systems including nanoparticles and lipid-based systems, for example, solid nano-emulsions, and their impact on immune cells and generation of a memory effect are discussed. Moreover, challenges for TCI are addressed, including timely and targeted delivery of antigens and adjuvants to APCs within the skin as well as a deeper understanding of the ill-defined mechanisms leading to the induction of effective memory responses.
Collapse
Affiliation(s)
- Jonas Pielenhofer
- Biopharmaceutics and Pharmaceutical Technology, Johannes Gutenberg-University, Mainz, Germany
| | - Julian Sohl
- Third Department of Medicine - Hematology, Oncology, Pneumology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
| | - Maike Windbergs
- Institute of Pharmaceutical Technology, Buchmann Institute for Molecular Life Sciences, Goethe-University, Frankfurt, Germany
| | - Peter Langguth
- Biopharmaceutics and Pharmaceutical Technology, Johannes Gutenberg-University, Mainz, Germany
| | - Markus P Radsak
- Third Department of Medicine - Hematology, Oncology, Pneumology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
| |
Collapse
|
11
|
Bialojan A, Sohl J, Rausch J, Aranda Lopez P, Denny M, Langguth P, Hartmann AK, Yagita H, Probst HC, Schild H, Radsak MP. Transcutaneous immunization with CD40 ligation boosts cytotoxic T lymphocyte mediated antitumor immunity independent of CD4 helper cells in mice. Eur J Immunol 2019; 49:2083-2094. [PMID: 31393597 DOI: 10.1002/eji.201848039] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2018] [Revised: 05/22/2019] [Accepted: 08/06/2019] [Indexed: 11/07/2022]
Abstract
Transcutaneous immunization (TCI) is a novel vaccination strategy that utilizes skin-associated lymphatic tissue to induce immune responses. Employing T-cell epitopes and the TLR7 agonist imiquimod onto intact skin mounts strong primary, but limited memory CTL responses. To overcome this limitation, we developed a novel imiquimod-containing vaccination platform (IMI-Sol) rendering superior primary CD8+ and CD4+ T-cell responses. However, it has been unclear whether IMI-Sol per se is restricted in terms of memory formation and tumor protection. In our present work, we demonstrate that the combined administration of IMI-Sol and CD40 ligation unleashes fullblown specific T-cell responses in the priming and memory phase, strongly enhancing antitumor protection in mice. Interestingly, these effects were entirely CD4+ T cell independent, bypassing the necessity of helper T cells. Moreover, blockade of CD70 in vivo abrogated the boosting effect of CD40 ligation, indicating that the adjuvant effect of CD40 in TCI is mediated via CD70 on professional APCs. Furthermore, this work highlights the so far underappreciated importance of the CD70/CD27 interaction as a promising adjuvant target in TCI. Summing up, we demonstrate that the novel formulation IMI-Sol represents a powerful vaccination platform when applied in combination with sufficient adjuvant thereby overcoming current limitations of TCI.
Collapse
Affiliation(s)
- Ariane Bialojan
- Third Department of Medicine - Hematology, Oncology, Pneumology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
| | - Julian Sohl
- Third Department of Medicine - Hematology, Oncology, Pneumology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
| | - Johanna Rausch
- Third Department of Medicine - Hematology, Oncology, Pneumology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
| | - Pamela Aranda Lopez
- Third Department of Medicine - Hematology, Oncology, Pneumology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
| | - Mark Denny
- Biopharmaceutics and Pharmaceutical Technology, Johannes Gutenberg-University, Mainz, Germany
| | - Peter Langguth
- Biopharmaceutics and Pharmaceutical Technology, Johannes Gutenberg-University, Mainz, Germany
| | - Ann-Kathrin Hartmann
- Third Department of Medicine - Hematology, Oncology, Pneumology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.,Institute of Immunology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
| | - Hideo Yagita
- Department of Immunology, Juntendo University, Tokyo, Japan
| | - Hans Christian Probst
- Institute of Immunology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
| | - Hansjörg Schild
- Institute of Immunology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
| | - Markus P Radsak
- Third Department of Medicine - Hematology, Oncology, Pneumology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
| |
Collapse
|
12
|
Kaurav M, Kumar R, Jain A, Pandey RS. Novel Biomimetic Reconstituted Built-in Adjuvanted Hepatitis B Vaccine for Transcutaneous Immunization. J Pharm Sci 2019; 108:3550-3559. [PMID: 31348940 DOI: 10.1016/j.xphs.2019.07.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2019] [Revised: 07/12/2019] [Accepted: 07/17/2019] [Indexed: 02/06/2023]
Abstract
Transcutaneous immunization is the administration of a vaccine on the skin to generate efficient systemic and mucosal immune responses against an antigen. In the present study, reconstituted hepatitis B surface antigen vesicles (HBsAg-REVs) integrated with monophosphoryl lipid A were prepared by the delipidation-reconstitution method and tested as built-in adjuvanted vaccine, system for transcutaneous immunization using a combined approach of tape strippings, and enhanced antigen skin contact time. Prepared vesicles were extensively characterized for size, shape, zeta potential, and antigen protein loading efficiency. Following topical application, HBsAg-REVs skin permeation on isolated rat skin and cell uptake by bone marrow-derived dendritic cells were determined by confocal laser scanning microscopy and flow cytometry, respectively. The humoral and cellular immune responses elicited by HBsAg-REVs via transcutaneous immunization were comparable to the marketed intramuscular hepatitis B vaccine formulation with predefined immunization protocols. This study supports that delivery of reconstituted HBsAg vesicles via transcutaneous route may open a new vista for designing topical vaccines with possible immune protection against hepatitis B in future.
Collapse
Affiliation(s)
- Monika Kaurav
- SLT Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya, Bilaspur, Chhattisgarh 495009, India
| | - Rajendra Kumar
- National UGC Centre of Excellence in NanoBiomedical Applications, Panjab University, Chandigarh 160014, India
| | - Atul Jain
- National UGC Centre of Excellence in NanoBiomedical Applications, Panjab University, Chandigarh 160014, India
| | - Ravi Shankar Pandey
- SLT Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya, Bilaspur, Chhattisgarh 495009, India.
| |
Collapse
|
13
|
Pattarabhiran SP, Saju A, Sonawane KR, Manimaran R, Bhatnagar S, Roy G, Kulkarni RB, Venuganti VVK. Dissolvable Microneedle-Mediated Transcutaneous Delivery of Tetanus Toxoid Elicits Effective Immune Response. AAPS PharmSciTech 2019; 20:257. [PMID: 31332640 DOI: 10.1208/s12249-019-1471-3] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2019] [Accepted: 07/08/2019] [Indexed: 11/30/2022] Open
Abstract
Transcutaneous immunization using a microneedle device presents a promising alternative to syringe-based injection of vaccines. The aim of this study was to investigate the effective immune response elicited after application of tetanus toxoid antigen-loaded dissolvable microneedles (TT-MN) in mice model. Dissolvable microneedles were prepared using 20% w/v of polyvinyl alcohol and polyvinyl pyrrolidone polymer mixture by micromolding technique. TT-MN were prepared by addition of tetanus toxoid to polymer mixture before casting microneedles. TT-MN were characterized using texture analyzer, stereomicroscope, and scanning electron microscope. Tetanus toxoid loading was found to be 77 ± 2 μg per microneedle array. Confocal microscopic analysis showed that the microneedles penetrated to a depth of 130 μm inside mouse skin. Complete dissolution of microneedles was achieved within 1 h after insertion in skin. Immunization studies in Swiss albino mice demonstrated significantly (p < 0.001) greater IgG, IgG1, and IgG2a antibody titers for TT-MN and intramuscular injection groups compared with naïve control. Splenocyte proliferation assay confirmed effective re-stimulation on exposure to tetanus toxoid in microneedle treatment groups. Taken together, TT-MN can be developed as minimally invasive system for transcutaneous delivery of tetanus toxoid antigen.
Collapse
|
14
|
Sun X, Zeng L, Huang Y. Transcutaneous delivery of DNA/mRNA for cancer therapeutic vaccination. J Gene Med 2019; 21:e3089. [PMID: 30958606 DOI: 10.1002/jgm.3089] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2019] [Revised: 03/17/2019] [Accepted: 03/22/2019] [Indexed: 12/11/2022] Open
Abstract
Therapeutic vaccination is a promising strategy for the immunotherapy of cancers. It eradicates cancer cells by evoking and strengthening the patient's own immune system. Because of the easy access and sophisticated immune networks, the skin becomes an ideal target organ for vaccination. Genetic vaccines have been widely investigated, with the advantages of the delivery of multiple antigens and a lower cost for production compared to protein/peptide vaccines. This review summarizes the advances made with respect to the transcutaneous delivery of DNA/mRNA for cancer therapeutic vaccination and also gives a brief description of the immunological milieu of the skin and the importance of dendritic cell-targeting in vaccine delivery, as well as the technologies that aim to facilitate antigen delivery and modulate antigen-presenting cells, thus improving cellular responses. The applications of genetic vaccines encoding tumor antigens delivered through the skin route, both in preclinical and clinical trials, are outlined.
Collapse
Affiliation(s)
- Xiaoyi Sun
- School of Medicine, Zhejiang University City College, Hangzhou, China
| | - Linghui Zeng
- School of Medicine, Zhejiang University City College, Hangzhou, China
| | - Yongzhuo Huang
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
| |
Collapse
|
15
|
Bussio JI, Molina-Perea C, González-Aramundiz JV. Lower-Sized Chitosan Nanocapsules for Transcutaneous Antigen Delivery. Nanomaterials (Basel) 2018; 8:E659. [PMID: 30149658 DOI: 10.3390/nano8090659] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/25/2018] [Revised: 08/14/2018] [Accepted: 08/22/2018] [Indexed: 11/17/2022]
Abstract
Transcutaneous vaccination has several advantages including having a noninvasive route and needle-free administration; nonetheless developing an effective transdermal formulation has not been an easy task because skin physiology, particularly the stratum corneum, does not allow antigen penetration. Size is a crucial parameter for successful active molecule administration through the skin. Here we report a new core-shell structure rationally developed for transcutaneous antigen delivery. The resulting multifunctional carrier has an oily core with immune adjuvant properties and a polymeric corona made of chitosan. This system has a size of around 100 nm and a positive zeta potential. The new formulation is stable in storage and physiological conditions. Ovalbumin (OVA) was used as the antigen model and the developed nanocapsules show high association efficiency (75%). Chitosan nanocapsules have high interaction with the immune system which was demonstrated by complement activation and also did not affect cell viability in the macrophage cell line. Finally, ex vivo studies using a pig skin model show that OVA associated to the chitosan nanocapsules developed in this study penetrated and were retained better than OVA in solution. Thus, the physicochemical properties and their adequate characteristics make this carrier an excellent platform for transcutaneous antigen delivery.
Collapse
|
16
|
Mittal R, Parrish JM, Soni M, Mittal J, Mathee K. Microbial otitis media: recent advancements in treatment, current challenges and opportunities. J Med Microbiol 2018; 67:1417-1425. [PMID: 30084766 DOI: 10.1099/jmm.0.000810] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Otitis media (OM) is a common disease affecting humans, especially paediatric populations. OM refers to inflammation of the middle ear and can be broadly classified into two types, acute and chronic. Bacterial infection is one of the most common causes of OM. Despite the introduction of vaccines, the incidence of OM remains significantly high worldwide. In this mini-review article, we discuss the recent treatment modalities for OM, such as suspension gel, transcutaneous immunization, and intranasal and transtympanic drug delivery, including therapies that are currently undergoing clinical trials. We provide an overview of how these recent advancements in therapeutic strategies can facilitate the circumvention of current treatment challenges involving preadolescence soft palate dysfunction, biofilm formation, tympanic membrane (ear drum) barrier and the attainment of efficacious drug concentrations in the middle ear. While traditional first-line immunization strategies are generally not very efficacious against biofilms, new technologies that use transdermal or intranasal drug delivery via chitosan-PsaA nanoparticles have shown promising results in experimental animal models of OM. Sustained drug delivery systems such as penta-block copolymer poloxamer 407-polybutylphosphoester (P407-PBP) or poloxamer 407 (e.g. OTO-201, with the brand name 'OTIPRIO') have demonstrated that treatments can be reduced to a single topical application. The emergence of effective new treatment modalities opens up promising new avenues for the treatment of OM that could lead to improved quality of life for many children and their families.
Collapse
Affiliation(s)
- Rahul Mittal
- 1Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, FL, USA
| | - James M Parrish
- 1Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Manasi Soni
- 1Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Jeenu Mittal
- 1Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Kalai Mathee
- 2Department of Human and Molecular Genetics, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA.,3Biomolecular Sciences Institute, Florida International University, Miami, FL, USA
| |
Collapse
|
17
|
Qiu Y, Guo L, Zhang S, Xu B, Gao Y, Hu Y, Hou J, Bai B, Shen H, Mao P. DNA-based vaccination against hepatitis B virus using dissolving microneedle arrays adjuvanted by cationic liposomes and CpG ODN. Drug Deliv 2015; 23:2391-2398. [PMID: 25625495 DOI: 10.3109/10717544.2014.992497] [Citation(s) in RCA: 66] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
DNA vaccines are simple to produce and can generate strong cellular and humoral immune response, making them attractive vaccine candidates. However, a major shortcoming of DNA vaccines is their poor immunogenicity when administered intramuscularly. Transcutaneous immunization (TCI) via microneedles is a promising alternative delivery route to enhance the vaccination efficacy. A novel dissolving microneedle array (DMA)-based TCI system loaded with cationic liposomes encapsulated with hepatitis B DNA vaccine and adjuvant CpG ODN was developed and characterized. The pGFP expression in mouse skin using DMA was imaged over time. In vivo immunity tests in mice were performed to observe the capability of DMA to induce immune response after delivery of DNA. The results showed that pGFP could be delivered into skin by DMA and expressed in skin. Further, the amount of expressed GFP was likely to peak at day 4. The immunity tests showed that the DMA-based DNA vaccination could induce effective immune response. CpG ODN significantly improved the immune response and achieved the shift of immune type from predominate Th2 type to a balance Th1/Th2 type. The cationic liposomes could further improve the immunogenicity of DNA vaccine. In conclusion, the novel DMA-based TCI system can effectively deliver hepatitis B DNA vaccine into skin, inducing effective immune response and change the immune type by adjuvant CpG ODN.
Collapse
Affiliation(s)
- Yuqin Qiu
- a Key Laboratory of Photochemical Conversion and Optoelectronic Materials , Technical Institute of Physics and Chemistry, Chinese Academy of Sciences , Haidian , Beijing , China , and
| | - Lei Guo
- a Key Laboratory of Photochemical Conversion and Optoelectronic Materials , Technical Institute of Physics and Chemistry, Chinese Academy of Sciences , Haidian , Beijing , China , and
| | - Suohui Zhang
- a Key Laboratory of Photochemical Conversion and Optoelectronic Materials , Technical Institute of Physics and Chemistry, Chinese Academy of Sciences , Haidian , Beijing , China , and
| | - Bai Xu
- a Key Laboratory of Photochemical Conversion and Optoelectronic Materials , Technical Institute of Physics and Chemistry, Chinese Academy of Sciences , Haidian , Beijing , China , and
| | - Yunhua Gao
- a Key Laboratory of Photochemical Conversion and Optoelectronic Materials , Technical Institute of Physics and Chemistry, Chinese Academy of Sciences , Haidian , Beijing , China , and
| | - Yan Hu
- b 302 Military Hospital of China , Fengtai , Beijing , China
| | - Jun Hou
- b 302 Military Hospital of China , Fengtai , Beijing , China
| | - Bingke Bai
- b 302 Military Hospital of China , Fengtai , Beijing , China
| | - Honghui Shen
- b 302 Military Hospital of China , Fengtai , Beijing , China
| | - Panyong Mao
- b 302 Military Hospital of China , Fengtai , Beijing , China
| |
Collapse
|
18
|
Matsuo K, Okamoto H, Kawai Y, Quan YS, Kamiyama F, Hirobe S, Okada N, Nakagawa S. Vaccine efficacy of transcutaneous immunization with amyloid β using a dissolving microneedle array in a mouse model of Alzheimer’s disease. J Neuroimmunol. 2014;266:1-11. [PMID: 24315156 DOI: 10.1016/j.jneuroim.2013.11.002] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2013] [Revised: 11/02/2013] [Accepted: 11/05/2013] [Indexed: 12/26/2022]
Abstract
Vaccine therapy for Alzheimer's disease (AD) based on the amyloid cascade hypothesis has recently attracted attention for treating AD. Injectable immunization using amyloid β peptide (Aβ) comprising 1-42 amino-acid residues (Aβ1-42) as antigens showed therapeutic efficacy in mice; however, the clinical trial of this injected Aβ1-42 vaccine was stopped due to the incidence of meningoencephalitis caused by excess activation of Th1 cells infiltrating the brain as a serious adverse reaction. Because recent studies have suggested that transcutaneous immunization (TCI) is likely to elicit Th2-dominant immune responses, TCI is expected to be effective in treating AD without inducing adverse reactions. Previously reported TCI procedures employed complicated and impractical vaccination procedures; therefore, a simple, easy-to-use, and novel TCI approach needs to be established. In this study, we investigated the vaccine efficacy of an Aβ1-42-containing TCI using our novel dissolving microneedle array (MicroHyala; MH) against AD. MH-based TCI induced anti-Aβ1-42 immune responses by simple and low-invasive application of Aβ1-42-containing MH to the skin. Unfortunately, this TCI system resulted in little significant improvement in cognitive function and Th2-dominant immune responses, suggesting the need for further modification.
Collapse
|
19
|
Frolov VG, Seid RC, Odutayo O, Al-Khalili M, Yu J, Frolova OY, Vu H, Butler BA, Look JL, Ellingsworth LR, Glenn GM. Transcutaneous delivery and thermostability of a dry trivalent inactivated influenza vaccine patch. Influenza Other Respir Viruses 2008; 2:53-60. [PMID: 19453472 PMCID: PMC4941894 DOI: 10.1111/j.1750-2659.2008.00040.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
A patch containing a trivalent inactivated influenza vaccine (TIV) was prepared in a dried, stabilized formulation for transcutaneous delivery. When used in a guinea pig immunogenicity model, the dry patch was as effective as a wet TIV patch in inducing serum anti-influenza IgG antibodies. When the dry TIV patch was administered with LT as an adjuvant, a robust immune response was obtained that was comparable with or better than an injected TIV vaccine. When stored sealed in a nitrogen-purged foil, the dry TIV patch was stable for 12 months, as measured by HA content, under both refrigerated and room temperature conditions. Moreover, the immunological potency of the vaccine product was not affected by long-term storage. The dry TIV patch was also thermostable against three cycles of alternating low-to-high temperatures of -20/25 and -20/40 degrees C, and under short-term temperature stress conditions. These studies indicate that the dry TIV patch product can tolerate unexpected environmental stresses that may be encountered during shipping and distribution. Because of its effectiveness in vaccine delivery and its superior thermostable characteristics, the dry TIV patch represents a major advance for needle-free influenza vaccination.
Collapse
|